Leonard Jason

Leonard A. Jason, PhD, is a professor of psychology at DePaul University in Chicago, Illinois, USA and Director of the Center for Community Research at DePaul University which includes the Depaul University Chronic Fatigue Syndrome Project. He was a voting member of the Health and Human Services's CFSAC committee from 04/01/07-04/01/11.

Dr. Jason developed chronic fatigue syndrome after contracting infectious mononucleosis in 1989, necessitating a leave of absence from his university job for a year and a half. After recovering enough to return to work, he began studying chronic fatigue syndrome: “What I found was that the illness had a lousy name, chronic fatigue syndrome,” he recalled. “It had an even worse case definition. The tests used to assess people’s psychological conditions were inappropriate. The treatments being used were inappropriate. And the prevalence data was not very good. So I said to myself, ‘Boy, I’m gonna have business for the next 20 years.’” He has become one of the most respected and prolific researchers of chronic fatigue syndrome.

In 2008, David Tuller profiled for The New York Times Dr. Jason's experience as both living with and researching myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

Education

 * 1975 - Ph.D., Clinical/Community Psychology, University of Rochester, Rochester, New York
 * 1971 - B.A., Psychology, Brandeis University, Waltham, Massachusetts

Awards

 * 2015, American Psychological Association’s award for Distinguished Professional Contributions to Applied Research
 * 2013, DePaul University College of Science and Health award for Excellence in Research
 * 2011, Rudy Perpich Senior Lectureship Award, presented to a distinguished CFS/FM scientist, physician or healthcare worker awarded by IACFS/ME
 * 2011, Tom Fellows award for outstanding contributions to the Oxford House organization
 * 1997, CSN ACTION Champion Award from the Chronic Fatigue Immune Dysfunction Syndrome Association of America (CAA)

Open letter to The Lancet
Two open letters to the editor of The Lancet urged the editor to commission a fully independent review of the PACE trial, which the journal had published in 2011. The first, written in 2015, was sign by Dr. Jason and 5 of his colleagues. In 2016, thirty-six additional colleagues in the ME/CFS field, signed the second letter.
 * 13 November 2015, An open letter to Dr. Richard Horton and The Lancet
 * 10 February 2016, An open letter to The Lancet, again - Virology blog

Pediatric case definition

 * 2006, "A Pediatric Case Definition for Myalgic Encephalomyelitis and Chronic Fatigue Syndrome""'Summary: For a diagnosis of chronic fatigue syndrome (CFS), most researchers use criteria that were developed by Fukuda et al. (1994), with modifications suggested by Reeves et al. (2003). However, this case definition was established for adults rather than children. A Canadian Case Definition (ME/CFS; Myalgic Encephalomyelitis/CFS) has recently been developed, with more specific inclusion criteria (Carruthers et al., 2003). Again, the primary aim of this case definition is to diagnose adult CFS. A significant problem in the literature is the lack of both a pediatric definition of ME/CFS and a reliable instrument to assess it. These deficiencies can lead to criterion variance problems resulting in studies labeling children with a wide variety of symptoms as having ME/CFS. Subsequently, comparisons between articles become more difficult, decreasing the possibility of conducting a meta-analysis. This article presents recommendations developed by the International Association of Chronic Fatigue Syndrome Pediatric Case Definition Working group for a ME/CFS pediatric case definition. It is hoped that this pediatric case definition will lead to more appropriate identification of children and adolescents with ME/CFS.'"

Studies

 * 2017, Clinical criteria versus a possible research case definition in chronic fatigue syndrome/myalgic encephalomyelitis
 * 2017, Article - "The PACE trial missteps on pacing and patient selection""Abstract - 'As others have pointed out a variety of complicating factors with the PACE trial (e.g. changing outcome criteria), I will limit my remarks to issues that involve the composition of adaptive pacing therapy and issues involving patient selection. My key points are that the PACE trial investigators were not successful in designing and implementing a valid pacing intervention and patient selection ambiguity further compromised the study’s outcomes.'"
 * 2017, A Prospective Study of Infectious Mononucleosis in College Students"'Abstract - Background: The present study aims to prospectively investigate possible biological and psychological factors present in college students who will go on to develop chronic fatigue syndrome (CFS) following Infectious Mononucleosis (IM). Identification of risk factors predisposing patients towards developing CFS may help to understand the underlying mechanisms and ultimately prevent its occurrence. Our study is enrolling healthy college students over the age of 18. Enrollment began in March of 2013 and is ongoing. Methods: Biological and psychological data are collected when students are well (Stage 1), when they develop IM (Stage 2), and approximately 6 months after IM diagnosis (Stage 3). Results: Two case studies demonstrate the progression of student symptomology across all three stages. Conclusion: The Case Studies presented illustrate the usefulness of a prospective research design that tracks healthy.'"
 * 2016, Comparing the DePaul Symptom Questionnaire with physician assessments: a preliminary study"'Results: The DSQ identified 60 and the physicians identified 56 as having a CCC diagnosis. The overall agreement between the two ratings on the diagnostic assessment part was moderate (Kappa = 0.45, p < .001). The sensitivity of DSQ was good (98%) while the specificity was 38%. Positive and negative predictive values were 92% and 75%, respectively. Conclusion: DSQ is useful for detecting and screening symptoms consistent with a CCC diagnosis in clinical practice and research. However, it is important for initial screening of self-report symptoms to be followed up by subsequent medical and psychiatric examination in order to identify possible exclusionary medical and psychiatric disorders.'"
 * 2016, Housebound versus nonhousebound patients with myalgic encephalomyelitis and chronic fatigue syndrome"'Abstract - Objectives: The objective of this study was to examine individuals with myalgic encephalomyelitis and chronic fatigue syndrome who are confined to their homes due to severe symptomatology. The existing literature fails to address differences between this group, and less severe, nonhousebound patient populations. Methods: Participants completed the DePaul Symptom Questionnaire, a measure of myalgic encephalomyelitis and chronic fatigue syndrome symptomology, and the SF-36, a measure of health impact on physical/mental functioning. ANOVAs and, where appropriate, MANCOVAS were used to compare housebound and nonhousebound patients with myalgic encephalomyelitis and chronic fatigue syndrome across areas of functioning, symptomatology, and illness onset characteristics. Results: Findings indicated that the housebound group represented one quarter of the sample, and were significantly more impaired with regards to physical functioning, bodily pain, vitality, social functioning, fatigue, post-exertional malaise, sleep, pain, neurocognitive, autonomic, neuroendocrine, and immune functioning compared to individuals who were not housebound. Discussion: Findings indicated that housebound patients have more impairment on functional and symptom outcomes compared to those who were not housebound. Understanding the differences between housebound and not housebound groups holds implications for physicians and researchers as they develop interventions intended for patients who are most severely affected by this chronic illness.'"
 * 2016, Estimating the disease burden of ME/CFS in the United States and its relation to research funding "'Abstract: At the National Institutes of Health (NIH), burden of disease is an important factor in funding decisions along with such factors as scientific opportunity, the quality of the science, and the interest of researchers. Recent studies have quantified the burden for a number of diseases in the United States and the NIH has used that information to analyze how its own funding patterns correspond to disease burden. However, the burden of disease has not been quantified for myalgic encephalomyelitis, also called chronic fatigue syndrome (ME/CFS) and is often underestimated due to a lack of research and the misperceptions about the nature of the disease...Even given the limitations arising from sparse data, this analysis demonstrates that federal research funding for this disease is far less than what would be expected by the burden of the disease. We conclude that the annual research funding for ME/CFS would need to increase twenty-five fold or more to be commensurate with disease burden. This level of funding would best leverage the growing interest of researchers and the significant scientific opportunities that exist to understand the pathology of this disease and to advance diagnostics and treatments.'"
 * 2016, Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis"'Abstract:It is unclear what key symptoms differentiate Myalgic Encephalomyelitis (ME) and Chronic Fatigue syndrome (CFS) from Multiple Sclerosis (MS). The current study compared self-report symptom data of patients with ME or CFS with those with MS. The self-report data is from the DePaul Symptom Questionnaire, and participants were recruited to take the questionnaire online. Data were analyzed using a machine learning technique called decision trees. Five symptoms best differentiated the groups. The best discriminating symptoms were from the immune domain (i.e., flu-like symptoms and tender lymph nodes), and the trees correctly categorized MS from ME or CFS 81.2% of the time, with those with ME or CFS having more severe symptoms. Our findings support the use of machine learning to further explore the unique nature of these different chronic diseases.'"
 * 2016, Mortality in patients with myalgic encephalomyelitis and chronic fatigue syndrome
 * 2016, Deconstructing [[post-exertional malaise]: An exploratory factor analysis.] "'Abstract: Post-exertional malaise is a cardinal symptom of myalgic encephalomyelitis and chronic fatigue syndrome. There are two differing focuses when defining post-exertional malaise: a generalized, full-body fatigue and a muscle-specific fatigue. This study aimed to discern whether post-exertional malaise is a unified construct or whether it is composed of two smaller constructs, muscle fatigue and generalized fatigue. An exploratory factor analysis was conducted on several symptoms that assess post-exertional malaise. The results suggest that post-exertional malaise is composed of two empirically different experiences, one for generalized fatigue and one for muscle-specific fatigue.'"
 * 2016, Assessing current functioning as a measure of significant reduction in activity level "Abstract - Background: Myalgic encephalomyelitis and chronic fatigue syndrome have case definitions with varying criteria, but almost all criteria require an individual to have a substantial reduction in activity level. Unfortunately, a consensus has not been reached regarding what constitutes substantial reductions. One measure that has been used to measure substantial reduction is the Medical Outcomes Study Short-Form-36 Health Survey (SF-36). Purpose: The current study examined the relationship between the SF-36, a measure of current functioning, and a self-report measure of the percent reduction in hours spent on activities. Results: Findings indicated that select subscales of the SF-36 accurately measure significant reductions in functioning. Further, this measure significantly differentiates patients from controls. Conclusion: Determining what constitutes a significant reduction in activity is difficult because it is subjective to the individual. However, certain subscales of the SF-36 could provide a uniform way to accurately measure and define substantial reductions in functioning.
 * 2016, The Role of Infectious and Stress-related Onsets in Myalgic Encephalomyelitis and Chronic Fatigue Syndrome Symptomatology and Functioning
 * 2016, Educational Priorities for Healthcare Providers and Name Suggestions for Chronic Fatigue Syndrome: Including the Patient Voice
 * 2016, qEEG / LORETA in Assessment of Neurocognitive Impairment in a Patient with Chronic Fatigue Syndrome: A Case Report (Marcie Zinn, Mark Zinn, Leonard Jason)
 * 2016, Case definitions integrating empiric and consensus perspectives
 * 2016, Comparing the DePaul Symptom Questionnaire with physician assessments: a preliminary study"'Results: The DSQ identified 60 and the physicians identified 56 as having a CCC diagnosis. The overall agreement between the two ratings on the diagnostic assessment part was moderate (Kappa = 0.45, p < .001). The sensitivity of DSQ was good (98%) while the specificity was 38%. Positive and negative predictive values were 92% and 75%, respectively. Conclusion: DSQ is useful for detecting and screening symptoms consistent with a CCC diagnosis in clinical practice and research. However, it is important for initial screening of self-report symptoms to be followed up by subsequent medical and psychiatric examination in order to identify possible exclusionary medical and psychiatric disorders.'"
 * 2016, Housebound versus nonhousebound patients with myalgic encephalomyelitis and chronic fatigue syndrome"'Abstract - Objectives: The objective of this study was to examine individuals with myalgic encephalomyelitis and chronic fatigue syndrome who are confined to their homes due to severe symptomatology. The existing literature fails to address differences between this group, and less severe, nonhousebound patient populations. Methods: Participants completed the DePaul Symptom Questionnaire, a measure of myalgic encephalomyelitis and chronic fatigue syndrome symptomology, and the SF-36, a measure of health impact on physical/mental functioning. ANOVAs and, where appropriate, MANCOVAS were used to compare housebound and nonhousebound patients with myalgic encephalomyelitis and chronic fatigue syndrome across areas of functioning, symptomatology, and illness onset characteristics. Results: Findings indicated that the housebound group represented one quarter of the sample, and were significantly more impaired with regards to physical functioning, bodily pain, vitality, social functioning, fatigue, post-exertional malaise, sleep, pain, neurocognitive, autonomic, neuroendocrine, and immune functioning compared to individuals who were not housebound. Discussion: Findings indicated that housebound patients have more impairment on functional and symptom outcomes compared to those who were not housebound. Understanding the differences between housebound and not housebound groups holds implications for physicians and researchers as they develop interventions intended for patients who are most severely affected by this chronic illness.'"
 * 2016, The Relationship between Age and Illness Duration in Chronic Fatigue Syndrome"'Abstract:Chronic fatigue syndrome (CFS) is a debilitating illness, but it is unclear if patient age and illness duration might affect symptoms and functioning of patients. In the current study, participants were categorized into four groups based upon age (under or over age 55) and illness duration (more or less than 10 years). The groups were compared on functioning and symptoms. Findings indicated that those who were older with a longer illness duration had significantly higher levels of mental health functioning than those who were younger with a shorter or longer illness duration and the older group with a shorter illness duration. The results suggest that older patients with an illness duration of over 10 years have significantly higher levels of mental health functioning than the three other groups. For symptoms, the younger/longer illness duration group had significantly worse immune and autonomic domains than the older/longer illness group. In addition, the younger patients with a longer illness duration displayed greater autonomic and immune symptoms in comparison to the older group with a longer illness duration. These findings suggest that both age and illness duration need to be considered when trying to understand the influence of these factors on patients."
 * 2015, Caring for people with severe myalgic encephalomyelitis: An interpretative phenomenological analysis of parents’ experiences "'Abstract: Experiences of parents who care for sons or daughters with severe myalgic encephalomyelitis are rarely discussed within the literature. Narratives of parent–carers in Lost Voices from a Hidden Illness were analyzed using interpretative phenomenological analysis. This study aimed to give voices to those who care for individuals with myalgic encephalomyelitis and are often stigmatized and inform future research supporting parent–carers. Results included themes of identity change, guilt, feeling like outsiders, uncertainty, changing perceptions of time, coping mechanisms, and improvement/symptom management. Findings could inform the development of carer-focused interventions and provide vital information to health professionals about parent–carers’ lived experience.'"
 * 2015, Myalgic Encephalomyelitis: Symptoms and Biomarkers. (Marcie Zinn, Mark Zinn, Leonard Jason)
 * 2015, Functional level of patients with chronic fatigue syndrome reporting use of alternative vs. traditional treatments
 * 2015, Chronic fatigue syndrome versus systemic exertion intolerance disease
 * 2015, Variability in symptoms complicates utility of case definitions. Abstract
 * 2015, Comparing and contrasting consensus versus empirical domains. Abstract
 * 2015, Test–retest reliability of the DePaul Symptom Questionnaire Abstract"'Methods: Test–retest reliability of the measure was examined with a sample of 26 adults self-identifying as having either ME/CFS, ME, and/or CFS and 25 adults who did not self-identify as having these illnesses and were otherwise healthy controls. Results: Overall, the majority of items on the DSQ exhibited good to excellent test–retest reliability, with Pearson's or kappa correlation coefficients that were 0.70 or higher.'"
 * 2014, Validating a measure of myalgic encephalomyelitis/chronic fatigue syndrome symptomatology. Abstract"'Methods: Exploratory factor analysis (EFA) was used to establish the underlying factor structure of the DePaul Symptom Questionnaire (DSQ) using a well-characterized sample of individuals (92.6% met the Fukuda et al. criteria and/or the Clinical Canadian Criteria) and this structure was then tested on a less stringently recruited sample of individuals utilizing a confirmatory factor analysis (CFA). Convergent and discriminant validity of the DSQ were also examined utilizing alternative measures of symptomatology and functioning. Results: A three-factor solution was found using EFA (Neuroendocrine, Autonomic, and Immune Symptoms; Neurological/Cognitive Dysfunction; Post-Exertional Malaise) and the fit of this factor structure was adequate for the second sample. The DSQ was found to have good convergent and discriminant validity. Conclusions: The DSQ is a valid tool for assessing ME/CFS symptoms. There may be two core ME/CFS symptom clusters: post-exertional malaise and cognitive dysfunction.'"
 * 2014, Chronic Fatigue Syndrome: The Current Status and Future Potentials of Emerging Biomarkers. (FULL TEXT)
 * 2014, Predictors of post-infectious chronic fatigue syndrome in adolescents"'Abstract - This study focused on identifying risk factors for adolescent post-infectious chronic fatigue syndrome (CFS), utilizing a prospective, nested case–control longitudinal design in which over 300 teenagers with infectious mononucleosis (IM) were identified through primary care sites and followed. Baseline variables that were gathered several months following IM, included autonomic symptoms, days in bed since IM, perceived stress, stressful life events, family stress, difficulty functioning and attending school, family stress, and psychiatric disorders. A number of variables were predictors of post-infectious CFS at six months; however, when autonomic symptoms were used as a control variable, only days spent in bed since mono was a significant predictor. Step-wise logistic regression findings indicated that baseline autonomic symptoms as well as days spent in bed since mono, which reflect the severity of illness, were the only significant predictors of those who met CFS criteria at six months.'"
 * 2014, Examining case definition criteria for chronic fatigue syndrome and myalgic encephalomyelitis. Abstract
 * 2013, Energy conservation/envelope theory interventions. Full Text
 * 2013, The implications of sensitization and kindling for chronic fatigue syndrome
 * 2013, Contrasting chronic fatigue syndrome versus myalgic encephalomyelitis/chronic fatigue syndrome. Abstract
 * 2012, Antibody to Epstein-Barr Virus Deoxyuridine Triphosphate Nucleotidohydrolase and Deoxyribonucleotide Polymerase in a Chronic Fatigue Syndrome Subset (FULL TEXT)"Abstract - 'Background: A defined diagnostic panel differentiated patients who had been diagnosed with chronic fatigue syndrome (CFS), based upon Fukuda/Carruthers criteria. This diagnostic panel identified an Epstein-Barr virus (EBV) subset of patients (6), excluding for the first time other similar “clinical” conditions such as cytomegalovirus (CMV), human herpesvirus 6 (HHV6), babesiosis, ehrlichiosis, borreliosis, Mycoplasma pneumoniae, Chlamydia pneumoniae, and adult rheumatic fever, which may be mistakenly called CFS. CFS patients were treated with valacyclovir (14.3 mg/kg q6h) for ≥12 months. Each patient improved, based upon the Functional Activity Appraisal: Energy Index Score Healthcare Worker Assessment (EIPS), which is a validated (FSS-9), item scale with high degree of internal consistency measured by Cronbach's alpha. Methods: Antibody to EBV viral capsid antigen (VCA) IgM, EBV Diffuse Early Antigen EA(D), and neutralizing antibodies against EBV-encoded DNA polymerase and EBV-encoded dUTPase were assayed serially approximately every three months for 13–16 months from sera obtained from patients with CFS (6) and from sera obtained from twenty patients who had no history of CFS. Results: Antibodies to EBV EA(D) and neutralizing antibodies against the encoded-proteins EBV DNA polymerase and deoxyuridine triphosphate nucleotidohydrolase (dUTPase) were present in the EBV subset CFS patients. Of the sera samples obtained from patients with CFS 93.9% were positive for EA(D), while 31.6% of the control patients were positive for EBV EA(D). Serum samples were positive for neutralizing antibodies against the EBV-encoded dUTPase (23/52; 44.2%) and DNA polymerase (41/52; 78.8%) in EBV subset CFS patients, but negative in sera of controls. Conclusions: There is prolonged elevated antibody level against the encoded proteins EBV dUTPase and EBV DNA polymerase in a subset of CFS patients, suggesting that this antibody panel could be used to identify these patients, if these preliminary findings are corroborated by studies with a larger number of EBV subset CFS patients.'"
 * 2012, Minimum data elements for research reports on CFS. Full text "Abstract: 'Chronic fatigue syndrome (CFS) is a debilitating condition that has received increasing attention from researchers in the past decade. However, it has become difficult to compare data collected in different laboratories due to the variability in basic information regarding descriptions of sampling methods, patient characteristics, and clinical assessments. The issue of variability in CFS research was recently highlighted at the NIH's 2011 State of the Knowledge of CFS meeting prompting researchers to consider the critical information that should be included in CFS research reports. To address this problem, we present our consensus on the minimum data elements that should be included in all CFS research reports, along with additional elements that are currently being evaluated in specific research studies that show promise as important patient descriptors for subgrouping of CFS. These recommendations are intended to improve the consistency of reported methods and the interpretability of reported results. Adherence to minimum standards and increased reporting consistency will allow for better comparisons among published CFS articles, provide guidance for future research and foster the generation of knowledge that can directly benefit the patient.'"
 * 2009, Activity Logs as a Measure of Daily Activity Among Patients with Chronic Fatigue Syndrome. (Full text)
 * 2009, The impact of energy modulation on physical functioning and fatigue severity among patients with ME/CFS. (Full text)
 * 2008, The associations between basal salivary cortisol levels and illness symptomatology in chronic fatigue syndrome. (Full text) "'Abstract: Hypocortisolism has been reported in chronic fatigue syndrome (CFS), with the significance of this finding to disease etiology unclear. This study examined cortisol levels and their relationships with symptoms in a group of 108 individuals with CFS. CFS symptoms examined included fatigue, pain, sleep difficulties, neurocognitive functioning, and psychiatric status. Alterations in cortisol levels were examined by calculation of mean daily cortisol, while temporal variation in cortisol function was examined by means of a regression slope. Additionally, deviation from expected cortisol diurnal pattern was determined via clinical judgment. Results indicated that fatigue and pain were associated with salivary cortisol levels. In particular, variance from the expected pattern of cortisol was associated with increased levels of fatigue. The implications of these findings are discussed.'"
 * 2008, The Energy Envelope Theory and myalgic encephalomyelitis/chronic fatigue syndrome. (Full text)
 * 2006, Causes of death among patients with chronic fatigue syndrome
 * 2006, Differential diagnosis of chronic fatigue syndrome and major depressive disorder
 * 2003, Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition and recommendations for resolution
 * 2001, Assessing attitudes toward new names for chronic fatigue syndrome."'Abstract: A questionnaire was distributed at the American Association of Chronic Fatigue Syndrome's biannual convention in Washington in January 2001 as well as through various Internet Web sites and listserves during early February and March of 2001. The sample consisted of 432 respondents. Most respondents (86%) indicated they wanted a name change, although more patients than scientists were in favor of this change. It was also apparent that the patients and physicians were clearly split between adopting a name such as myalgic encephalopathy versus one such as neuro-endocrine immune disorder. Also, among those respondents who selected either of these two choices for a new name, less than 30% of them supported the other name. Although the majority of respondents feel the name should be changed at this time, this survey suggests there are different stakeholders involved in the name-change process, each with strong and sometimes disparate feelings about changing the name.'"
 * 2000, Chronic fatigue syndrome: sociodemographic subtypes in a community-based sample.
 * 1999, A Community-Based Study of Chronic Fatigue Syndrome "Results: There was a 65.1% completion rate for the telephone interviews during the first phase of the study. Findings indicated that CFS occurs in about 0.42% (95% confidence interval, 0.29%-0.56%) of this random community-based sample. The highest levels of CFS were consistently found among women, minority groups, and persons with lower levels of education and occupational status. Conclusions: Chronic fatigue syndrome is a common chronic health condition, especially for women, occurring across ethnic groups. Earlier findings suggesting that CFS is a syndrome primarily affecting white, middle-class patients were not supported by our findings."

Talks & Interviews

 * Mar 2017, Leonard Jason's Presentation to European Network on "Current Situation on Prevalence and Diagnostic Crieria for ME and CFS"
 * Jan 2017, Leonard Jason's talk to the Ethical Humanist Society of Chicago on "Understanding Unexplained Illness: From Knowledge to Action"     Slides for "Understanding Unexplained Illness: From Knowledge to Action"
 * 2016, Leonard Jason's comments at Sept. 27th, 2016 #millionsmissing protest in Chicago
 * 2016, 12th International IACFS/ME Biennial Clinical and Research Conference, Emerging Science and Clinical Care, Behavioral Assessment and Treatment of ME/CFS and Fibromyalgia(Workshop given with Fred Friedberg, Ph.D.)
 * Oct 2015, Defining essential features of myalgic encephalomyelitis and chronic fatigue syndrome (Sweden)]
 * 2015, DePaul Chili Challenge video
 * 2014, Leonard Jason answering questions from members of the Institute of Medicine panel on case definition issues

Invest in ME International ME Conference

 * 2010, Speaker at the 5th Invest in ME International ME Conference on Key Note Speech: How Case Definitions Can Stigmatize: Implications for Epidemiology, Etiology, and Pathophysiology DVD available
 * 2008, Speaker at the 3rd Invest in ME International ME Conference on Case Definitions of ME/CFS – including paediatric case definition DVD available

ME/CFS Alert

 * 2011, ME/CFS Alert Episode 10 - Dr. Leonard Jason, Pt. 3
 * 2011, ME/CFS Alert Episode 09 - Dr. Leonard Jason, Pt. 2
 * 2011, ME/CFS Alert Episode 08 - Dr. Leonard Jason, Pt. 1

Web seminars Science for Patients / Wetenschap voor patienten (The Netherlands, english spoken, dutch subtitles)

 * 2014, 50. Introduction - Experience with ME / Introductie - Ervaring met ME Prof. Leonard Jason
 * 2014, 51. Criteria and Diagnosis part 1 / Criteria en diagnose deel 1 - Prof. Leonard Jason
 * 2014, 52. Criteria and Diagnosis part 2 / Criteria en diagnose deel 2 - Prof. Leonard Jason
 * 2014, 53. ME versus Psychiatric Disorders / ME versus psychiatrische aandoeningen - Prof. Leonard Jason
 * 2014, 54. Treating and managing ME / Behandelen van en omgaan met ME -Prof. Leonard Jason
 * 2014, 55. Symptoms of ME and treatments / Symptomen van ME en behandelingen - Prof. Leonard Jason
 * 2014, 56. Population and Social Impact / Populatie en sociale gevolgen - Prof. Leonard Jason
 * 2014, 57. Future and Teaching about ME / Toekomst en onderwijs geven over ME - Prof. Leonard Jason

Books

 * 2008, Fatigue Science for Human Health, edited by Yatanabe, Y., Evengard, B., Natelson, B.H., Jason, L.A., & Kuratsune, H.
 * 2003, The Handbook of Chronic Fatigue Syndrome by Leonard Jason, Patricia Fennell and Renée R. Taylor.
 * 2001, Clinician's Guide To Controversial Illnesses: Chronic Fatigue Syndrome, Fibromyalgia, and Multiple Chemical Sensitivities, by Renee R. Taylor, Fred Friedberg, and Leonard A. Jason
 * 1998, Understanding Chronic Fatigue Syndrome: An Empirical Guide to Assessment and Treatment, by Fred Friedberg and Leonard Jason

Online Presence

 * Website
 * Twitter

Learn More

 * Wikipedia - Leonard Jason
 * Leonard Jason's Home Page at DePaul University